Loading the records…
Loading the records…
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
National Institutes of Health is planning to buy "RNA sequencing and whole genome sequencing services". This is an early notice: it is not taking bids yet. The work is in Bethesda, MD, USA. Responses are due Nov 6, 2026. In the last 2 years, similar work went to 10 or more companies, usually for about $157K per award. An award is expected between December 2026 and August 2027.
Put together from the facts on this page; the details and sources are below.
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Every notice posted under solicitation 75N98027Q00043 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
t. To achieve this, RNA sequencing will be provided for samples generated in the Staudt laboratory. RNA sequencing is essential for characterizing genome edits and conducting transcriptomic analysis. By utilizing Plasmidsaurus, a faster and more scalable alternative to traditional sequencing methods based on the latest Oxford Nanopore Technologies platform, we aim to generate results that will deepen our understanding of cellular mechanisms involved in B-cell lymphoma and guide future downstream experiments. RNA sequencing and Whole-genome sequencing are required to observe the effects of various drugs on gene expression, identify pathways, and discover novel pathways. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Plasmidsaurus uses the latest Oxford Nanopore Technologies platform, a faster, more scalable alternative to traditional sequencing. Using the latest Oxford Nanopore Technologies platform ensures accurate sequencing, which is crucial for reproducible experiments which will significantly advance our understanding of, and treatment for, B-cell lymphoma, which is vital to cancer research at the National Cancer Institute. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 6, 2026. Please reference Notice No. 75N98027Q00043 in the subject line of the submission.
11 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) Q301.
Single-winner award sizes (11): middle half $70K to $297K, median $157K; range $27K to $35.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AZENTA US INC | 1 | $35.0M | Dec 2, 2024 |
| PSOMAGEN INC | 1 | $533K | Dec 31, 2024 |
| NEW YORK STEM CELL FOUNDATION INC | 1 | $362K | Sep 23, 2025 |
| BAYLOR MIRACA GENETICS LABORATORIES LLC | 1 | $232K | Sep 26, 2025 |
| THE BROAD INSTITUTE, INC | 1 | $215K | Sep 29, 2026 |
| NORGEN BIOTEK CORP | 1 | $157K | Sep 19, 2025 |
| KAISER FOUNDATION HOSPITALS 1 KAISER PLAZA 22ND FLOOR Oakland CA 94612 USA | 1 | $115K | Sep 22, 2025 |
| ProteinTech Group Inc | 1 | $90K | Sep 19, 2025 |
| GREENWOOD GENETIC CENTER INC | 1 | $49K | Sep 25, 2025 |
| HISTOSERV, INC | 1 | $29K | May 5, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.